SCHEMBL680656

SCHEMBL680656

CCCc1cccc([N+](=O)[O-])c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.62
CYP1A2 P05177 2/20 0.58
CYP2C19 P33261 2/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
LMNA P02545 2/20 0.57
ALOX5 P09917 1/20 0.56
ALDH1A1 P00352 6/20 0.54
ACHE P22303 1/20 0.53
SIGMAR1 Q99720 2/20 0.51
MEN1 O00255 2/20 0.51
MAPT P10636 2/20 0.51
KMT2A Q03164 2/20 0.51
PYCR1 P32322 1/20 0.51
TDP1 Q9NUW8 2/20 0.49
KDM4E B2RXH2 1/20 0.49
CYP3A4 P08684 1/20 0.49
ALOX15 P16050 1/20 0.48
CNR1 P21554 1/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9172285 0.89 TSHR (0.59) TSHRCYP1A2CYP2C19CYP2D6CYP2C9
Dinitrophenylene SCHEMBL27675225 0.89 CYP1A2 (0.59) TSHRCYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL9175089 0.88 TSHR (0.57) TSHRCYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL24767335 0.86 TSHR (0.56) TSHRCYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL8733292 0.86 TSHR (0.56) TSHRCYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL10650120 0.85 TSHR (0.54) TSHRCYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL29385659 0.85 TSHR (0.67) TSHRCYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL132216 0.85 TSHR (0.67) TSHRCYP1A2CYP2C19CYP2D6CYP2C9
Nitrogen SCHEMBL9102089 0.84 TSHR (0.53) TSHRCYP1A2CYP2C19CYP2D6CYP2C9
Hydrochloric Acid SCHEMBL6961845 0.84 TSHR (0.53) TSHRCYP1A2CYP2C19CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103313964-A Intermediate compounds and methods for preparing fingolimod MAPI PHARMA LTD 2013-09-18 CN claimed
EP-1015402-B1 Method for producing compounds containing fluorine, in particular fluorobenzaldehydes and fluorobenzonitriles CLARIANT GMBH (DE) 2002-12-04 EP claimed
US-6166242-A Method for producing compounds containing fluorine, in particular fluorobenzaldhydes and fluorobenzonitriles AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) 2000-12-26 US claimed
CN-1268936-A Method for producing compound contg. fluorine, in particular fluorobenzaldhydes and fluorobnzonitriles AVENTIS RES & TECHNOLOGY GMBH (DE) 2000-10-04 CN claimed
EP-1015402-A1 METHOD FOR PRODUCING COMPOUNDS CONTAINING FLUORINE, IN PARTICULAR FLUOROBENZALDHYDES AND FLUOROBENZONITRILES Aventis Research & Technologies GmbH & Co. KG (DE) 2000-07-05 EP claimed
WO-1999011588-A1 METHOD FOR PRODUCING COMPOUNDS CONTAINING FLUORINE, IN PARTICULAR FLUOROBENZALDHYDES AND FLUOROBENZONITRILES AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) 1999-03-11 WO claimed
US-20240231230-A1 COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM NISSAN CHEMICAL CORPORATION (JP) 2024-07-11 US disclosed
US-20210186970-A1 SELECTIVE CALCIUM CHANNEL ANTAGONISTS NORTHWESTERN UNIVERSITY 2021-06-24 US disclosed
WO-2021113686-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 WO disclosed
US-20200377446-A1 METHOD FOR MANUFACTURING AROMATIC AZO COMPOUND FUJIFILM CORPORATION (JP) 2020-12-03 US disclosed
US-10639310-B2 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE CORPORATION (US) 2020-05-05 US disclosed
US-20190167685-A1 SELECTIVE CALCIUM CHANNEL ANTAGONISTS NORTHWESTERN UNIVERSITY 2019-06-06 US disclosed
US-20190125750-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2019-05-02 US disclosed
EP-1189929-A2 FACTOR VIIA INHIBITORS Aventis Pharma Deutschland GmbH (DE) 2002-03-27 EP disclosed
US-6166242-A Method for producing compounds containing fluorine, in particular fluorobenzaldhydes and fluorobenzonitriles AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) 2000-12-26 US disclosed
WO-2000075172-A2 FACTOR VIIa INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-12-14 WO disclosed
EP-1059302-A1 Factor VIIa inhibitors Aventis Pharma Deutschland GmbH (DE) 2000-12-13 EP disclosed
CN-1268936-A Method for producing compound contg. fluorine, in particular fluorobenzaldhydes and fluorobnzonitriles AVENTIS RES & TECHNOLOGY GMBH (DE) 2000-10-04 CN disclosed
EP-1015402-A1 METHOD FOR PRODUCING COMPOUNDS CONTAINING FLUORINE, IN PARTICULAR FLUOROBENZALDHYDES AND FLUOROBENZONITRILES Aventis Research & Technologies GmbH & Co. KG (DE) 2000-07-05 EP disclosed
WO-1999011588-A1 METHOD FOR PRODUCING COMPOUNDS CONTAINING FLUORINE, IN PARTICULAR FLUOROBENZALDHYDES AND FLUOROBENZONITRILES AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) 1999-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10639310-B2 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors JAK3, JAK1, JAK2 TSHR 3192/4885CYP1A2 1683/4885CYP2C19 1587/4885
US-20190167685-A1 SELECTIVE CALCIUM CHANNEL ANTAGONISTS CACNA1C, CACNA1B, CACNA1G TSHR 4014/4885CYP1A2 4681/4885CYP2C19 4851/4885
US-20200377446-A1 METHOD FOR MANUFACTURING AROMATIC AZO COMPOUND CYP4X1, ALDOA, PAH TSHR 4517/4885CYP1A2 15/4885CYP2C19 62/4885
US-20190125750-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 TSHR 3192/4885CYP1A2 1683/4885CYP2C19 1587/4885
US-20210186970-A1 SELECTIVE CALCIUM CHANNEL ANTAGONISTS CACNA1C, CACNA1B, CACNA1G TSHR 4014/4885CYP1A2 4681/4885CYP2C19 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.